Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.

Slides:

Advertisements

Similar presentations

Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.

Advertisements

Abbreviations: RECIST, Response Evaluation Criteria In Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease;

Mizutomo Azuma 1, Michael M. Shi 2, Christian J. Jacques 2, Carl Barrett 2, Kathleen D. Danenberg 3, Syma Iqbal 1, Anthony El-Khoueiry 1, Dongyun Yang.

Introduction Materials and Methods Results Conclusions CD133 Polymorphisms are associated with clinical outcome in metastatic colorectal cancer (mCRC)

Introduction Patients and Methods Results Conclusion Wnt signaling is essential for embryonic development, stem cells and tissue regeneration. Colorectal.

HIGHLIGHTS IN THE MANAGEMENT OF BREAST CANCER

KRAS is mutated in about 40% of colorectal cancers; it is the only validated predictive marker used in patients with metastatic CRC 1. It is also a negative.

Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.

Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman.

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Gianni L et al. Proc SABCS 2012;Abstract GS6-7.

Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.

A Micro RNA Polymorphism (MiRSNP) in 3’UTR of K-ras gene was associated with clinical outcome in mCRC patients treated with either single agent cetuximab.

Mizutomo Azuma 1, Dongyun Yang 2, Marinella Carpanu 3, Ellen Hollywood 3, Michael Lue-Yat 3, Wu Zhang 1, Kathleen D. Danenberg 4, Peter V. Danenberg 5,

Prospective study of EGFR intron 1 CA tandem repeats as predictive factor of benefit from cetuximab and irinotecan Antoniotti C 1, 2, Loupakis F 3, Cremolini.

Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,

Conclusion IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION (ANATOLIAN.

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide 1 Cereblon Expression Predicts.

*University Hospital Gasthuisberg, Leuven, Belgium

ICAM-1, GRP-78 and NFkB gene polymorphisms associated with clinical outcome in patients with metastatic colorectal cancer treated with first line 5-FU.

Introduction Results Material and Methods Conclusions Genetic variants predict clinical outcome clinical outcome in patients (pts) with metastatic colorectal.

Cancer Stem Cell SNPs Have Opposite Prognostic Outcome in Patients with Gastric Cancer Among Asian and Western Countries Melissa J. LaBonte 1, Takeru Wakatsuki.

Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.

Germline polymorphisms in the CD44 gene are associated with clinical outcome in localized gastric adenocarcinoma. Thomas Winder, M.D. University of Southern.

S. K. Anderson 1, J. M. Lafky 1, X. W. Carrero 1, T. K. Kimlinger 1, T. M. Halling 1, S. Kumar 1, P. J. Flynn 2, H. M. Gross 3, K. A. Jaeckle 4, J. C.

Mace L. Rothenberg, M.D. Professor of Medicine Ingram Professor of Cancer Research Biomarkers in Colorectal Cancer Management: KRAS Mutations and EGFR.

Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.

MABEL – a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan H Wilke, R Glynne-Jones, J Thaler,

Transcription Factor 7-like 2 (TCF7L2) Polymorphism Was Associated with Worse Survival in Three Independent Cohorts from the USA, Austria, and Japan Rita.

KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.

FC  RIIIa Receptor Polymorphisms Do Not Influence the Outcome of Treatment with Rituximab Followed by Active Immunotherapy with Mitumprotimut-T David.

Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Lonial.

Introduction Patients and Methods Results Conclusion Pericytes are a key component in the maturation of the VEGF driven tumor angiogenic process 1. Bevacizumab.

Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

12 th Annual CTOS Meeting 2006 AP23573 Induced Long-term Stability in 2 Patients with Desmoplastic Small Round Cell Tumor (#561) Scott Schuetze, Warren.

IntroductionPatient baseline characteristics Conclusion The process of EGFR recycling is important mechanism of resistance of cetuximab in colorectal cancer.

P.A. Tang 1, S. J. Cohen 1, G. Bjarnason 1, C. Kollmannsberger 1, K. Virik 1, M. J. MacKenzie 1, J. Brown 1, L. Wang 1, A. Chen 2, M. J. Moore 1 1 Princess.

Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,

Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC experience.

Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.

Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer In association.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

AR-V7 Splice Variant in Prostate Cancer : Taking Centre Stage

May 29 - June 2, 2015 KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1- Positive Extensive-Stage SCLC CCO Independent Conference.

Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in.

Samsung Genome Institute Samsung Medical Center

Higher Vitamin D Levels Associated With Improved Survival in Metastatic Colorectal Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

Metastatic Head Neck Cancer and Immunotherapy

University of Southern California, Norris Comprehensive Cancer Center

TBCRC (the translational breast cancer research consortium) 005 Prospective study

Vahdat L et al. Proc SABCS 2012;Abstract P

VEGF and VEGFR1 Gene expression levels predict tumor recurrence in adjuvant colon cancer Yan Ning1, Georg Lurje1, Kathleen Danenberg2, Janine Cooc2, Dongyun.

Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.

ASSOCIATIONS BETWEEN ANXA11 RS C/T, BTNL2 RS G/A, HLA CLASS I AND II POLYMORPHISMS AND SARCOIDOSIS EVOLUTION Manuel Vaz1, Bruno Lima2, Natália.

Intervista a Lucio Crinò

Genetic variants of kinases suppressors of Ras (KSR)in KRAS-BRAF

Progression-Free Survival Times Overall Survival Times

Published online September 20, 2017 by JAMA Surgery

Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The.

Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous.

Treated with Neoadjuvant Therapy

KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab Marta Schirripa1, Fotios Loupakis1, Chiara Cremolini1, Dongyun.

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell.

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Presentation transcript:

Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives The aim of the present study was to identify molecular predictors of response and survival to cetuximab by evaluating germline single nucleotide polymorphisms (SNPs) in genes involved in the following pathways to identify patients that benefit from this regimen: Genetic variants in immune response genes predict clinical outcome in mCRC patients treated with cetuximab-based therapy Anne M Schultheis 1, Nico B Volz 2, Wu Zhang 2, Dongyun Yang 2, Yan Ning 2, Sebastian Stintzing 2, Takeru Wakatsuki 2, Rita El-Khoueiry 2, Joseph Li 2, Adel Kardosh 2, Afsaneh Barzi 2, Anthony El-Khoueriy 2, Heinz-Josef Lenz 2 1 Institute of Pathology, University Hospital Cologne, Cologne, Germany; 2 USC/Norris Comprehensive Cancer Center, Los Angeles, CA Patient Characteristics Abstract ID: 3567 Results Cetuximab is a monoclonal antibody targeting the EGF-receptor 1. One of its anti-tumor mechanisms is the stimulation of the immune system via ADCC (Antibody-Dependent-Cell mediated Cytotoxicity) 2. Immune response through T-cell activation may also play a role in antitumor efficacy of chemotherapy. CTLA4, PDL1, IDO1 and CD24 are inhibitory co-receptors or ligands that may down-regulate the immune system through suppression of T-cell response 3,4,5. We tested whether germline polymorphisms in these genes are involved in the cetuximab dependent immune response pathway and thus predict outcome in mCRC patients treated with cetuximab. DNA was isolated from blood of 108 patients with mCRC treated with either irinotecan+cetuximab (n=73) or single agent cetuximab (n=35). Twelve prospectively functionally relevant SNPs; IDO1(rs , rs , rs ), PD1(rs , rs ), PDL1(rs , rs , rs , G>C), CTLA4(rs231777, rs231775), and CD24(rs8734) were analyzed by PCR-based direct sequencing and evaluated for association with tumor response, overall survival (OS), and progression free survival (PFS). Minor allele frequency had to be higher than 10%. PCR and product sequencing were done using standard procedures. There were 65 men and 43 women with a median PFS of 3.7 (95%CI: 2.8, 4.6) months and a median OS of 10.5 (95%CI:7.7, 13.3) months. Median follow up was 16.3 (range:1.2, 42.4) months. Uni- and multivariate analyses, adjusting for age, gender, rash and racial background, were carried out. After logistic regression analyses, baseline characteristics showing a p of <0.1 were included in the multivariate analysis. Kaplan-Meier estimation with log-rank testing for differences were carried out. References Our results suggest that SNPs in genes involved in immune response may predict efficacy of cetuximab treatment in patients with mCRC. To the best of our knowledge this is the first data linking PDL1(rs ) to cetuximab efficacy in mCRC patients. Studies to confirm these findings are warranted. PR = partial response, SD = stable disease, PD = progressive disease Table 2. Significant polymorphisms and clinical outcome in second-second line cetuximab therapy Figure 2-5. Univariate analysis OS and PFS Kaplan-Meier curves of significant polymorphisms. Figure 1. Genes involved in the immune response Pathways 1. Graham, J., et al. (2004). "Cetuximab." Nat Rev Drug Discov 3(7): Matsuo, T., et al. (2011). "Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models." BMC Res Notes 4: Kirkwood, J. M., et al. (2012). "Immunotherapy of cancer in 2012." CA Cancer J Clin 62(5): Vanneman, M. and G. Dranoff (2012). "Combining immunotherapy and targeted therapies in cancer treatment." Nat Rev Cancer 12(4): Li, O., et al. (2004). "CD24 expression on T cells is required for optimal T cell proliferation in lymphopenic host." J Exp Med 200(8): Baseline characteristics (n= 108)Primary outcome data (n = 108) Age: median (range) 64 years (35 – 110) Disease control rate (DCR)62.9 % Gendermale: 60% female: 40% Progression free survival (PFS) 3.7 months (2.8 – 4.6) Overall response rate (ORR) 20.0 %Overall survival (OS) 10.5 monthts (7.7 – 13.3) Figure 2. IDO1 rs shows a significant correlation between patients carrying the AA or AG genotype and longer OS. Figure 3. IDO1 rs shows a significant correlation between patients carrying the GG genotype and longer OS. Figure 4. CD24 rs8734 shows a significant correlation between patients carrying the GA genotype and longer OS. OS SNPNMedian, mo (95%CI) P (multivariate) IDO1rs A/A (5.7, 20.4) A/G (7.8, 15.9) G/G258.5 (5.1, 10.8) IDO1rs A/A (4.4, 15.0) A/G518.7 (6.3, 12.0) G/G (8.5, 26.4) CD24rs G/G547.8 (5.7, 10.5) G/A (8.7, 17.9) A/A52.3 (1.8, 11.3) PFS SNPNMedian, mo (95%CI) P (multivariate) CD24rs G/G543.6 (2.5, 4.6) G/A365.0 (3.3, 6.6) A/A51.3 (1.0, 3.3) CTLA4rs C/C654.1 (3.3, 5.3) C/T342.6 (2.3, 4.4) Tumor Response SNPNPRSD+PD PDL1rs P (multivariate) = G/G609 (16%)49 (84%) G/A367 (19%)29 (81%) A/A95 (56%)4 (44%) Figure 5. CD24 rs8734 shows a significant correlation between patients carrying the GA genotype and longer PFS.